The FY19 Defense Appropriation provides $7.5 million (M) to the Department of Defense Autism Research Program (ARP)to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

https://cdmrp.army.mil/funding/arp

Clinical Trial Award – Preapplication due May 1, 2019

• Investigators at or above the level of Associate Professor (or equivalent), or
• Early-Career Investigator Partnering PI Option: Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:
• • Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
  • Is no more than 7 years from the receipt of a terminal degree
  • Has the freedom to commit at least 50% time to the project
• Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
• Applications in the following areas are strongly encouraged:
• • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions.
  • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions.
  • Dissemination/Implementation of clinically validated interventions.
  • Improve diagnosis and access to services across the life span.
  • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
  • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
  • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services.
• Preliminary data relevant to the proposed clinical trial are required.
• Pre-application is required; application submission is by invitation only.
• Early-Career Investigator Partnering PI Option supports the development of young investigators .pursuing or wishing to pursue a career in ASD clinical trial research.
• The maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs).
• The maximum period of performance is 4 years.
• Early-Career Investigator Partnering PI Option:
• The maximum period of performance is 4 years.
• The maximum allowable funding for the entire period of performance is f $1,155,000 for direct costs (plus indirect costs).

Clinical Translational Research Award – Preapplication due May 1, 2019

• Investigators at or above the level of Assistant Professor (or equivalent)
• Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of ASD.
• Applications in the following areas are strongly encouraged:
• • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions.
  • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions.
  • Dissemination/implementation of clinically validated interventions.
  • Improve diagnosis and access to services across the life span.
  • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
  • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
  • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services.
• Preliminary data relevant to the proposed project are required.
• Pre-application is required; application submission is by invitation only.
• The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs).
• Maximum period of performance is 3 years

Idea Development Award – Preapplication due May1, 2019

• Investigators at or above the level of Assistant Professor (or equivalent), or
• Multiple PI Option: 
  Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator (PI) and receive a separate award. 
• Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes. 
• Applications in the following areas are strongly encouraged:
• • Assessment of novel therapeutics using valid preclinical models.
  • Environmental risk factors.
  • Mechanisms of heterogeneous clinical expression of ASD.
  • Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures, eating disorders, pharmacological side effects, gender dysphoria).
  • Factors promoting success in key transitions to inde78pence for individuals living with ASD.
  • Factors impacting quality of life during geographic relocation, such as military permanent change of station.
  • Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
  • Improve diagnosis and access to services across the life span.
  • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services.
  • Long-term treatment outcomes from previous clinical trials for ASD core symptoms or to alleviate co-occurring conditions.
• Preliminary data are required.
• Pre-application is required; application submission is by invitation only.
• Clinical trials or applications including a clinical trial aim are not allowed.
• Maximum funding of $500,000 for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP)to support innovative, high-impact prostate cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The PCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government.

The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease.  Applications submitted to the FY19 PCRP must address one or more of the program’s Overarching Challenges:

·         Improve the quality of life for survivors of prostate cancer

·         Develop treatments that improve outcomes for men with lethal prostate cancer

·         Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

·         Define the biology of lethal prostate cancer to reduce death

 

https://cdmrp.army.mil/pubs/press/2019/19pcrppreann

 

Early Investigator Research Award

By March 31, 2020, Postdoctoral Principal Investigators (PIs):

·         Must possess a doctoral degree (or equivalent)

·         Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)

·         Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.

·         PIs must have a designated mentor who is an experienced prostate cancer researcher.

·         Maximum funding of $200,000 for direct costs (plus indirect costs).

·         Maximum period of performance is 2 years.

 

Physician Research Award

At the time of application submission, the PI must be either:

·      In the last year of an accredited medical residency or medical fellowship program

·      or

·      Within 5 years of having initiated a faculty appointment (including Instructor positions)

·      Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.

·      PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.

·      PIs must have a designated mentor with an established research program in prostate cancer.

·     Maximum funding of $750K for direct costs (plus indirect costs).

·      Maximum period of performance is 4 years.

 

Idea Development Award

Established Investigators:  Independent investigators at all levels

Or

New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

·      Have the freedom to pursue individual aims without formal mentorship

·      Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award

·      Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)

·      Preproposal is required; application submission is by invitation only.

·      Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY19 PCRP Overarching Challenges.

·      Emphasis is equally placed on Innovation and Impact.

·      Preliminary data are encouraged, but not required.

·      Clinical trials are not allowed.

·      Each PI may submit only one application.

·      New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers

·      Established Investigators:

·      Maximum funding of $750,000 for direct costs (plus indirect costs).

·      New Investigators:

·      Maximum funding of $600,000 for direct costs (plus indirect costs)

·      Maximum period of performance is 3 years.

 

Health Disparity Research Award

Established Investigators:  Independent investigators at all levels

or

New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

·      Have the freedom to pursue individual aims without formal mentorship

·      Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award

·      Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)

·      Supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

·      Primary emphasis will be placed on the potential impact of the proposed work.

·      Preliminary data are encouraged, but not required.

·      Proposed projects may include basic, translational, population science, or clinical research, including clinical trials.

·      New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·      Established Investigators:

·      Maximum funding of $750,000 for direct costs (plus indirect costs).

·      New Investigators:

·      Maximum funding of $600,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

 

Translational Science Award

·      Independent investigators at all levels

·      Supports translational studies that will advance promising ideas into clinical applications.

·      The potential impact of the research is expected to be significant and go beyond an incremental advance.

·      Preliminary data to support feasibility are required.

·      Proposed projects may include basic, translational, population science or clinical research, but must demonstrate clinical relevance.

·      Maximum funding of $750,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

 

Clinical Trial Award

·      Independent investigators at all levels

·      Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II) to test interventions that will have a major impact on one or more of the FY19 PCRP Overarching Challenges.

·      Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types.

·      Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place by the time of application submission.

·      Letter of support to demonstrate proof of possession of sufficient drug supply to conduct study must be provided (if appropriate).

·      Clinical trials are expected to be initiated within 12 months of the award date.

·      Maximum funding of $2,000,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 4 years.

 

Synergistic Population and Data Science Award

·      Independent investigators with a faculty-level appointment (or equivalent)

·      Supports multi-institutional partnerships that will leverage existing prostate cancer patient databases and cohorts to address high-impact questions responsive to the FY19 PCRP Overarching Challenges.

·      Allows for development of infrastructure to facilitate the implementation of research ideas across databases, as well as conducting hypothesis-based studies utilizing the multi-institutional databases/cohorts.

·      Minimum of three institutions and three patient databases and/or cohorts is required.

·      Maximum funding of $1,500,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $16 million (M) to the Department of Defense Parkinson’ Research Program (PRP) to support research to understand, prevent, diagnose, and treat Parkinson’s disease.  Applications to the FY19 PRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The PRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

 

IMPORTANT:  The PRP seeks to focus applications and direct funding by providing Focus Areas to address the critical needs in Parkinson’s disease research. 

https://cdmrp.army.mil/pubs/press/2019/19prppreann

Investigator-Initiated Research Award

Independent investigators at or above the level of assistant professor (or equivalent)

• ·        Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research and/or patient care.
• ·        Preliminary data to support feasibility are required.  Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team.

·        Preliminary data to support feasibility required

• ·        Clinical trials not allowed

Partnering PI Option:

• ·        Provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.
• ·        PIs are expected to demonstrate within the application the synergistic components that will significantly advance the project, such that the research outcomes could not otherwise be accomplished through the independent efforts of a single PI.
• ·        The proposed partnership should result in a level of productivity that is greater than that achievable by each PI independently. 
• ·        Applications to this award mechanism must address at least one of the four FY19 Focus Areas noted below:
• ·        Clinical and research applications of digital health technology for Parkinson’s disease monitoring, including early identification
• ·        Mechanisms of non-motor symptoms of Parkinson’s disease from basic biology to clinical application
• ·        Sleep biology in Parkinson’s disease
• ·        Quantifiable gene-environment interactions and the risk of Parkinson’s disease

Individual PI:

·       Maximum funding of $1.5 million (M) in total costs

·       Maximum period of performance 3 years

Partnering PI Option:

·       Maximum funding of $2.4M in total costs

• ·       Maximum period of performance 3 years

 

Early Investigator Research Award

Postdoctoral or clinical fellow, instructor, or assistant professor within 10 years of advanced degree or residency training (or equivalent)

Verification of eligibility criteria must be provided in an Eligibility Statement signed by an appropriate institutional official and the PI. 

• ·         The EIRA supports early-career investigators exploring innovative, high-impact ideas or new technologies applicable to Parkinson’s disease research and/or patient care. The PRP seeks applications from investigators working in a broad spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research.
• ·         The application should demonstrate the PI’s potential for, and commitment to, pursuing a career in Parkinson’s disease research under the guidance of a designated Mentor(s). Evaluated criteria will include mentorship and mentorship environment with an identified path to independence.

·         Preliminary data not required

·         Clinical trials not allowed

• ·         Applications to this award mechanism must address at least one of the four FY19 Focus Areas.

·         Maximum funding of $360,000 in total costs

• ·         Maximum period of performance 2 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriations Act provides $15 million (M) to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact NF research.  Applications to the FY19 NFRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 NFRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

https://cdmrp.army.mil/funding/nfrp

Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY19 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY19 NFRP.  If the proposed research project does not address one of the FY19 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

• ·         Health services research
• –         Evidence-based best clinical practices
• §  Outcomes of specific therapies, including surgery and radiation therapy
• –         Implementation and access to NF-specific healthcare
• –         Utilization of technology and informatics
• ·         Heterogeneity of NF-related tumors
• ·         Non-tumor manifestations
• –         Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, and self-reported and underreported manifestations
• ·         Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches
• –         Transition from benign to malignant
• ·         Nutritional, environmental, and other modifiers of NF
• ·         Preclinical efficacy studies
• ·         Target identification, drug discovery
• ·         Targeted immunotherapies
•  

Clinical Trial Award – Letter of Intent due May 23, 2019

Must be at or above the level of Assistant Professor (or equivalent).

·         Supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (NF)

·         Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis.  Combinations of phases are permitted.

·         Funding must support a clinical trial and may not be used for preclinical studies.

·         Scientific rationale and preliminary data required for Phase I, II clinical trial applications.

·       Maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 for direct costs if requesting the Qualified Collaborator Option).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• ·       Maximum period of performance is 4 years

 

Exploration – Hypothesis Development Award – Letter of Intent due May 23, 2019

Investigators at all academic levels (or equivalent)

·         Supports the initial exploration of innovative, high-risk, high-gain concepts in NF research.

·         Preliminary and/or published data encouraged but not required.

·         Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

·         Clinical trials not allowed.

·       The maximum allowable funding for the entire period of performance is of $100,000 in direct costs.

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• ·       Maximum period of performance is 2 years
•  

New Investigator Award – Letter of Intent due May 23, 2019

Must be either:

An independent investigator at or below the level of Assistant Professor (or equivalent) and must plan to commit at least 30% of his/her effort toward the proposed research project; or

An established investigator in an area other than NF at or above the level of Assistant Professor seeking to transition into a career in NF research and must plan to commit at least 10% of his/her effort toward the proposed research project.

To be eligible, applicants may not have received more than $300,000 in direct costs for NF research as a Principal Investigator of one or more Federally funded, non-mentored peer reviewed grants.

·       Supports the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research.

·       Prior experience in NF research is not required.

·       Preliminary and/or published data relevant to NF and the proposed research project is required.

·       Clinical trials not allowed

·      The maximum allowable funding for the entire period of performance is $450,000 in direct costs.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·      Maximum period of performance is 3 years

 

Early Investigator Research Award – Letter of Intent due May 23, 209

The investigator must:

Be involved in postdoctoral training or medical residency program; and

Possess at least 1 and up to 4 years of continuous postdoctoral research experience by the Early Investigator Research Award application submission deadline; and

Possess a clinical doctoral degree (i.e., Ph.D., M.D. /Ph.D., D.O. /Ph.D.) or a clinical doctoral degree (i.e., M.D. /D.O. or Ph.D. in a clinical discipline) from an accredited organization or program.

·      Supports NF-focused research opportunities for individuals in the early stages of their careers.

·      Investigators must have a designated mentor who is an experienced NF researcher.

·      The maximum allowable funding for the entire period of performance is $200,000 in direct costs.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·      Maximum period of performance is 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY19 Defense Appropriation provides $3 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP)to support scientifically meritorious research focused on BMF diseases.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The BMFRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 BMFRP Program Announcements and General Application Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

https://cdmrp.army.mil/pubs/press/2019/19bmfrppreann

Idea Development Award

Established Investigators: 

• Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from first faculty appointment or

Early Career Investigators:

• Investigators at the level of Assistant Professor (or equivalent) and less than 10 years from first faculty appointment.
• Preproposal is required; full application submission is by invitation only.
• Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF.
• Strong BMF research team.
• May include relevant preliminary data.
• Clinical trials will not be supported.
• Maximum funding of $325,000 in direct costs (plus indirect costs)
• Period of performance not to exceed 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Multiple Sclerosis Research Program (MSRP)to support pioneering concepts and high-impact research that are relevant to the prevention, etiology, pathogenesis, assessment, and treatment of multiple sclerosis (MS) to ultimately lessen its personal and societal impact.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The MSRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 MSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

Applications submitted to the FY19 MSRP must address at least one of the following Focus Areas:

1. Factors That Promote Central Nervous System Regenerative Potential in Demyelination

Supports innovative mechanistic studies and translational approaches to promote axonal protection, regeneration, or remyelination in MS and/or relevant experimental models. 

Note:  Studies addressing the following topics will not be considered for funding: developmental myelination, dysmyelination, blood-brain barrier permeability, basic mechanisms of demyelination, neurodegeneration, or inflammatory mechanisms and anti-inflammatory therapeutic strategies that limit tissue injury secondarily.

1. Correlates of Disease Activity and Progression in MS

Supports the identification and/or validation of correlates of disease activity and progression using pre-existing specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered patient cohorts.

Note:  The study must leverage pre-existing specimens and/or data that are available at the time of application submission; collection of a single set of specimens and/or data collected at one additional time point from participants in the existing cohort is allowed.

1. Biology and Measurement of MS Symptoms

Supports studies on the biology and measurement of MS symptoms, which may include pain, fatigue, depression, anxiety, loss of bladder control, impaired mobility, and cognitive, motor, visual, or sexual dysfunction. 

Note:  Studies of disease-modifying or regenerative therapies that secondarily impact MS symptoms will not be considered for funding under this Focus Area.

 

 

 

Exploration – Hypothesis Development Award

Independent investigators at or above the level of Assistant Professor (or equivalent)

·         Pre-application submission is required; application submission is by invitation only.

·         Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.

·         Preliminary data not required.

• Clinical trials not allowed.

·         Maximum funding of $150,000 for direct costs (plus indirect costs)

• Maximum period of performance is 2 years.
•  

 

Investigator-Initiated Research Award

Independent investigators at or above the level of Assistant Professor (or equivalent)

·         Pre-application submission is required; application submission is by invitation only.

·         Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.

·         Preliminary data required.

• Clinical trials not allowed.

·         Maximum funding of $600,000 for direct costs (plus indirect costs)

• Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP home page at https://eBRAP.org.  For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriations Act provides $15 million (M) to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact NF research.  Applications to the FY19 NFRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The NFRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 NFRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY19 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY19 NFRP.  If the proposed research project does not address one of the FY19 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

• ·        Health services research
• –       Evidence-based best clinical practices
• §  Outcomes of specific therapies, including surgery and radiation therapy
• –       Implementation and access to NF-specific healthcare
• –       Utilization of technology and informatics

• Heterogeneity of NF-related tumors
• Non-tumor manifestations

• Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, and self-reported and underreported manifestations

• ·        Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches

• Transition from benign to malignant

• ·        Nutritional, environmental, and other modifiers of NF
• ·        Preclinical efficacy studies
• ·        Target identification, drug discovery
• ·        Targeted immunotherapies

Clinical Trial Award

Independent investigators at or above the level of Assistant Professor (or equivalent).

·        Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.

·        Funding must support a clinical trial and may not be used for preclinical studies.

·        Scientific rationale and preliminary data required for Phase I, II clinical trial applications.

·      Maximum funding of $800,000 for direct costs (plus indirect costs)

·      Maximum funding of $1,000,000 for direct costs (plus indirect costs) for applications including a Collaborator

• ·      Maximum period of performance is 4 years

Exploration – Hypothesis Development Award

All academic levels (or equivalent)

·        Funds the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in NF research.

·        Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

·        Preliminary and/or published data is encouraged but not required.

·        Clinical trials not allowed.

·      Maximum funding of $100,000 for direct costs (plus indirect costs)

• ·      Maximum period of performance is 2 years

Investigator-Initiated Research Award

Independent investigators at or above the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period throughout the entirety of the award.

·       Funds highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.

·       Optional Features: Applications meeting criteria identified in the announcement may apply for a higher level of funding for the following options: Qualified Collaborator and/or NF Open Science Initiative (NF-OSI).

·       Preliminary and/or published data is required.

·       Clinical trials not allowed.

·     Maximum funding of $525,000 for direct costs (plus indirect costs)

·     Maximum funding of $575,000 for direct costs (plus indirect costs) for applications including either an Optional Qualified Collaborator or NF-OSI option

·     Maximum funding of $625,000 for direct costs (plus indirect costs) for applications including both, an Optional Qualified Collaborator and the NF-OSI

·     Maximum period of performance is 3 years

New Investigator Award

Independent investigators at or below the level of Assistant Professor (or equivalent) or an established investigator at or above the level of Assistant Professor seeking to transition into a career in NF research.

·      Supports the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research.

·      Experience in NF research is allowed, but not required.

·      Preliminary and/or published data is required.

·      Clinical trials not allowed

·     Maximum funding of $450,000 for direct costs (plus indirect costs)

·     Maximum period of performance is 3 years

Early Investigator Research Award

Postdoctoral Ph.D. or M.D. PIs:

·   Must have successfully defended a doctoral thesis or possess an M.D. degree, and Have at least 3 years and up to 6 years of consecutive postdoctoral fellowship

·     Supports research opportunities focused on NF for individuals in the early stages of their careers.

·     PIs must have a designated mentor who is an experienced NF researcher.

·     Maximum funding of $200,000 for direct costs (plus indirect costs)

·     Maximum period of performance is 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $90 million (M) to the U.S. Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in early April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY19 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, or ovarian cancer will not be accepted.

The FY19 PRCRP Topic Areas are:

·         Bladder cancer ·         Blood cancers ·         Brain cancer ·         Cancer in children, adolescents, and young adults*

·         Colorectal cancer ·         Immunotherapy† ·         Listeria vaccine for cancer ·         Liver cancer ·         Lymphoma ·         Mesothelioma

·         Neuroblastoma ·         Pancreatic cancer ·         Pediatric brain tumors ·         Rare cancersǂ ·         Stomach cancer

*The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between 15 and 39 years of age.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s). Research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^†As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

^ǂRare cancer is defined by the National Cancer Institute as a cancer that occurs in fewer than 15 out of 100,000 people each year.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

The FY19 PRCRP Military Relevance Focus Areas are listed below:

It is central to the vision and mission of the PRCRP that applications address how the proposed research is related to military health and mission readiness of both deployed and non-deployed personnel, their dependents, retirees, and Veterans. The FY19 PRCRP requires all applications to respond to at least one of Military Relevance Focus Areas listed below:

• Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
• Gaps in cancer prevention, early detection/diagnosis, prognosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public

Career Development Award

Principal Investigator (PI): Independent early-career investigator within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research. 

·         Letter of Intent is required.  An invitation to submit a full application is not required.

·         Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.

·         Must address at least one of the FY19 PRCRP Topic Areas.

·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

·         Preliminary data are not required.

·         Clinical trials are not allowed.

·       Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 3 years.

 

Horizon Award

Principal Investigator (PI):

Predoctoral candidate within 2 years of completion of required coursework/laboratory rotations, successfully passed qualifying examinations, and is working in his/her Mentor’s laboratory application submission deadline.

Or

Postdoctoral fellow within 3 years of completion of terminal degree and is working in his/her Mentor’s laboratory at application submission deadline.

Mentor: Investigators at or above the level of Assistant Professor (or equivalent); must have a proven publication and funding record in cancer research. 

PI and Mentor must be at the same organization.

·         Letter of Intent is required.  An invitation to submit a full application is not required.

·         Supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor).

·         Must address at least one of the FY19 PRCRP Topic Areas.

·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

·         Preliminary data are not required.

·         Clinical trials are not allowed.

·       Maximum funding for the entire period of performance is $150,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 2 years.

 

Idea Award with Special Focus

Independent investigator with a faculty-level appointment (or equivalent).

·         Preproposal is required; application submission is by invitation only.

·         Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to Service members, their families, and other military beneficiaries.

·         Emphasis on innovation and military relevance/impact.

·         Must address at least one of the FY19 PRCRP Topic Areas.

·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

·         Preliminary data are not required.

·         Clinical trials are not allowed.

·       Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 2 years.

 

Impact Award

Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to submit an application.

·         Preproposal is required; application submission is by invitation only.

·         Supports hypothesis-driven, high impact research.

·         Encourages applications that support research projects or ideas that specifically focus on critical scientific and clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on one of the FY19 PRCRP Topic Areas.

·         Must address at least one of the FY19 PRCRP Topic Areas.

·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

·         Preliminary data are required.

·         Clinical Trials are allowed.

·       Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 3 years.

 

Translational Team Science Award

At least two and up to three PIs must partner in one overarching correlative or translational research study.

At least one of the PIs is encouraged to be a military or US Department of Veterans Affairs investigator.

·         Preproposal is required; application submission is by invitation only.

·         Emphasizes multi-PI, multidisciplinary collaborations.

·         Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research relevant to Service members, their families, and other military beneficiaries.

·         Not intended to support high throughput screenings, sequencing, etc.

·         Must address at least one of the FY19 PRCRP Topic Areas.

·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

·         Preliminary data are required.

·         Clinical Trials are allowed.

·       Maximum funding for the entire period of performance is $1,500,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 4 years.

 

A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $14 million (M) to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 LCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

Applications submitted to the FY19 LCRP must address at least one of the nine Areas of Emphasis listed below:

• Identify innovative strategies for the screening and early detection of lung cancer.
• Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
• Identify innovative strategies for prevention of the occurrence of lung cancer.
• Identify innovative strategies for the treatment of lung cancer.
• Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
• Develop or optimize predictive markers to assist with therapeutic decision-making.
• Understand mechanisms of resistance to treatment (primary and secondary).
• Understand contributors to lung cancer development other than tobacco.
• Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

Military Relevance:  The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families.  Military relevance will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review.  Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

• Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
• Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
• Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area
• Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
• Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

https://cdmrp.army.mil/pubs/press/2019/19lcrppreann

Concept Award

• Investigators at all academic levels
• Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.
• Emphasis on innovation.
• Clinical trials not allowed.
• Preliminary data discouraged.
• Military relevance strongly encouraged.
• Maximum funding of $100,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 1 year.

Career Development Award

• Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment
• Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
• Clinical trials not allowed.
• Preliminary data not required.
• Military relevance strongly encouraged. Mentor:  At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research
• Maximum funding of $250,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Idea Development Award

• Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
• New Investigators:  Investigators that meet the following criteria at the application submission deadline date:
• Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award
• Are within 10 years of first faculty appointment (or equivalent)
• Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
• Emphasis on innovation and impact.
• New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
• Clinical trials not allowed.
• Preliminary data required, but may be from outside of lung cancer.
• Military relevance strongly encouraged.
• Maximum funding of $350,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Investigator-Initiated Translational Research Award

• Independent investigators at or above the level of Assistant Professor (or equivalent)
• Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.
• This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
• • Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts
  • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug submission
  • Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials
• Preliminary data required, but may be from outside of lung cancer.
• Military relevance strongly encouraged.
• Maximum funding of $400,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Translational Research Partnership Award

• Investigators at or above the level of Assistant Professor (or equivalent)
• Supports partnerships between clinicians and research scientists that accelerate ideas in lung cancer into clinical applications.
• • One partner is strongly encouraged to be from either a Military Treatment Facility or a VA medical center.
• Non-Traditional Partnerships are encouraged.
• Small-scale clinical trials allowed.
• Preliminary data required, but may be from outside of lung cancer.
• Military relevance strongly encouraged.
• Maximum combined funding of $900,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Focus Areas:  The goal of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in tuberous sclerosis complex (TSC), from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY19 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY19 Focus Areas:

• Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
• Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
• Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions
• Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization

https://cdmrp.army.mil/funding/tscrp

Exploration – Hypothesis Development Award – Letter of Intent due April 18, 2019

• Investigators at all academic levels (or equivalent), including postdoctoral fellows
• Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.
• Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
• Preliminary data are not required.
• Clinical trials not allowed.
• The maximum allowable funding for the entire period of performance is $150,000 in direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• Maximum period of performance is 2 year

Idea Development Award – Letter of Intent due April 18, 2019

Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);

Or New Investigators:  Independent investigator at or below the level of Assistant Professor (or equivalent); or Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC.

• Supports ideas that have the potential to yield high-impact findings and new avenues of investigation.
• Preliminary data are expected.
• Clinical trials not allowed.
• New Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in TSC research.
• Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately
• The maximum allowable funding for the entire period of performance is $450,000 for direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• Maximum period of performance is 3 years

Clinical Translational Research Award – Letter of Intent due April 18, 2019

• Independent investigators at or above the level of Assistant Professor (or equivalent)
• Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.
• Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest.
• Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 
• Preclinical studies may be appropriate but must include a clinical component.
• Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
• Projects that are exploratory and/or strictly animal research will not be considered for funding.
• Preliminary data required.
• The maximum allowable funding for the entire period of performance is $600,000 in direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism isl also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org